Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Catalyst Pharm Inc (CPRX)

Catalyst Pharm Inc (CPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,792,561
  • Shares Outstanding, K 122,912
  • Annual Sales, $ 491,730 K
  • Annual Income, $ 163,890 K
  • EBIT $ 296 M
  • EBITDA $ 334 M
  • 60-Month Beta 0.72
  • Price/Sales 4.99
  • Price/Cash Flow 9.24
  • Price/Book 3.01

Options Overview Details

View History
  • Implied Volatility 62.34% (-15.07%)
  • Historical Volatility 24.16%
  • IV Percentile 81%
  • IV Rank 36.01%
  • IV High 120.40% on 10/14/25
  • IV Low 29.68% on 08/19/25
  • Expected Move (DTE 4) 0.95 (4.19%)
  • Put/Call Vol Ratio 0.18
  • Today's Volume 265
  • Volume Avg (30-Day) 465
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 6,840
  • Open Int (30-Day) 6,987
  • Expected Range 21.77 to 23.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.47
  • Number of Estimates 3
  • High Estimate 0.54
  • Low Estimate 0.32
  • Prior Year 0.66
  • Growth Rate Est. (year over year) -28.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.15 +2.57%
on 01/06/26
25.14 -9.63%
on 12/15/25
+0.17 (+0.75%)
since 12/09/25
3-Month
19.90 +14.17%
on 10/14/25
25.14 -9.63%
on 12/15/25
+1.90 (+9.13%)
since 10/09/25
52-Week
19.05 +19.27%
on 09/25/25
26.58 -14.52%
on 06/09/25
-0.08 (-0.35%)
since 01/08/25

Most Recent Stories

More News
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies

CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...

CPRX : 22.72 (+0.53%)
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)

CORAL GABLES, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The University of Notre Dame and Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical...

CPRX : 22.72 (+0.53%)
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...

CPRX : 22.72 (+0.53%)
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...

CPRX : 22.72 (+0.53%)
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™

CORAL GABLES, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...

CPRX : 22.72 (+0.53%)
Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference

CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...

CPRX : 22.72 (+0.53%)
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue...

CPRX : 22.72 (+0.53%)
Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work

CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...

CPRX : 22.72 (+0.53%)
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference

CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...

CPRX : 22.72 (+0.53%)
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025

CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...

CPRX : 22.72 (+0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights...

See More

Key Turning Points

3rd Resistance Point 23.59
2nd Resistance Point 23.38
1st Resistance Point 23.05
Last Price 22.72
1st Support Level 22.51
2nd Support Level 22.30
3rd Support Level 21.97

See More

52-Week High 26.58
Fibonacci 61.8% 23.70
Fibonacci 50% 22.81
Last Price 22.72
Fibonacci 38.2% 21.93
52-Week Low 19.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar